For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- MPC Required Additional Report on Fibrinogen Product
May 13, 2002
- Nifedipine Effects Equivalent to those of ACE Inhibitors: Bayer
May 13, 2002
- Secondary Prevention Implementation Rate Needs to Be Increased: JHSF Survey
May 13, 2002
- Toxicogenomic Project Aims at Safety Prediction System
May 13, 2002
- REGULATORY NEWS IN BRIEF
May 13, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
May 13, 2002
- Kenporen, JMA Share Opinions on Review of Medical Fees
May 13, 2002
- 6 New Switch OTC Drugs Recommended for Approval
May 13, 2002
- Specialist System for Surgeons to Begin from June
May 13, 2002
- OTC NEWS IN BRIEF
May 13, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 13, 2002
- WORLD NEWS IN BRIEF
May 13, 2002
- President-elect Kobori to Follow Handa's Policy: MPC
May 13, 2002
- DIAGNOSTIC NEWS IN BRIEF
May 13, 2002
- SSP, Kirin Screen New LMW Compounds for Drug Discovery
May 13, 2002
- MEDICAL DEVICE NEWS IN BRIEF
May 13, 2002
- Sumitomo Agrees with GSK on Naratripan
May 13, 2002
- The South Africa Clinical Trial Mission
May 13, 2002
- Takeda Restructures Intellectual Property Department
May 13, 2002
- BULLETIN
May 13, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…